Bruton tyrosine kinase (BTK) and B-cell lymphoma-2 (BCL-2) inhibitors have been widely used to treat CLL, but CLL cells become resistant to these treatments over time. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.